Abstract

Contact PD/PI: FITZGERALD, GARRET A OVERALL ABSTRACT/SUMMARY The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the past decade the specific aims of ITMAT have been and remain (i) to increase the number of investigators capable of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of people. The two priorities of our CTSA are to foster the field of translational therapeutics and to bridge the pediatric to adult divide across the entire spectrum of clinical and translational science. This section describes how these priorities have influenced the growth of this CTSA Hub and outlines our plans for the coming funding period. Project Summary/Abstract Page 103 Contact PD/PI: FITZGERALD, GARRET A OVERALL NARRATIVE The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the past decade the specific aims of ITMAT have been and remain (i) to increase the number of investigators capable of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of people.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
1UL1TR001878-01
Application #
9261656
Study Section
Special Emphasis Panel (ZTR1-SRC (99))
Program Officer
Wilde, David B
Project Start
2016-07-01
Project End
2021-05-31
Budget Start
2016-07-01
Budget End
2017-05-31
Support Year
1
Fiscal Year
2016
Total Cost
$9,985,391
Indirect Cost
$2,775,398

  Institution

Name
University of Pennsylvania
Department
Pharmacology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104

  Publications

Rodríguez-Soto, Ana E; Langham, Michael C; Abdulmalik, Osheiza et al. (2018) MRI quantification of human fetal O2 delivery rate in the second and third trimesters of pregnancy. Magn Reson Med 80:1148-1157
Rossidis, Avery C; Stratigis, John D; Chadwick, Alexandra C et al. (2018) In utero CRISPR-mediated therapeutic editing of metabolic genes. Nat Med 24:1513-1518
Alonso, Estella M; Ye, Wen; Hawthorne, Kieran et al. (2018) Impact of Steroid Therapy on Early Growth in Infants with Biliary Atresia: The Multicenter Steroids in Biliary Atresia Randomized Trial. J Pediatr 202:179-185.e4
Han, Yuchi; Forfia, Paul R; Vaidya, Anjali et al. (2018) Rationale and design of the ranolazine PH-RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension. Open Heart 5:e000736
Guo, Lili; Wang, Qingqing; Weng, Liwei et al. (2018) Liquid Chromatography-High Resolution Mass Spectrometry Analysis of Platelet Frataxin as a Protein Biomarker for the Rare Disease Friedreich's Ataxia. Anal Chem 90:2216-2223
Tapia, Ignacio E; Marcus, Carole L (2018) Fitting Positive Airway Pressure Adherence into Teenage Life: Don't Push It! Ann Am Thorac Soc 15:22-23
Rickels, Michael R; DuBose, Stephanie N; Toschi, Elena et al. (2018) Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes. Diabetes Care 41:1909-1916
Schwartz, Gregory W; Petrovic, Jelena; Zhou, Yeqiao et al. (2018) Differential Integration of Transcriptome and Proteome Identifies Pan-Cancer Prognostic Biomarkers. Front Genet 9:205
Shah, Preya; Bassett, Danielle S; Wisse, Laura E M et al. (2018) Mapping the structural and functional network architecture of the medial temporal lobe using 7T MRI. Hum Brain Mapp 39:851-865
Thompson, Alexis A; Walters, Mark C; Kwiatkowski, Janet et al. (2018) Gene Therapy in Patients with Transfusion-Dependent ?-Thalassemia. N Engl J Med 378:1479-1493

Showing the most recent 10 out of 80 publications